Cognition Therapeutics (CGTX) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cognition Therapeutics (CGTX) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 49.1% versus a loss of 64.4%. Over five years, MIST leads with a -87.9% price change compared with -92.5% for CGTX. Milestone Pharmaceuticals is the larger company by market cap ($88.7 million vs $85.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | MIST |
|---|---|---|
| Share price | $0.8952 | $0.7121 |
| Market cap | $85.13M | $88.66M |
| 1-day change | -4.42% | -5.96% |
| YTD return | -33.69% | -64.75% |
| 1-year return | -49.14% | -64.39% |
| 5-year return | -92.48% | -87.93% |
| EPS (TTM) | $-0.17 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $3.06 |
| 52-week low | $0.55 | $0.709 |
| Distance from 52-week high | -56.33% | -76.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +271.98% | +722.92% |
| Average volume | 534.62K | 1.40M |
| Shares outstanding | 95.09M | 124.50M |
| Employees | 14 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGTX has outperformed MIST by 15.3 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
CGTX vs MIST FAQ
Which is bigger, Cognition Therapeutics or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $88.66M compared with $85.13M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or MIST?
CGTX returned -49.14% over the past 12 months, compared with -64.39% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Milestone Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cognition Therapeutics and Biotechnology: Pharmaceutical Preparations for Milestone Pharmaceuticals.